ArticleFrontiers in oncology2023

Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients.

Ema Mosleh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.